Keith Gottlieb, PhD, brings over 20 years of experience in clinical immunology and vaccine development to gene therapy, having held senior leadership roles at Vaxart, Emergent BioSolutions, and Focus Diagnostics. At Vaxart, he provided strategic leadership for norovirus, influenza, and COVID-19 vaccine programs, advancing them from the laboratory to Phase I and II, and established a GCLP laboratory for clinical development and regulatory submissions. At Emergent BioSolutions, he led the development and validation of vaccine immunogenicity assays for the Chikungunya vaccine Phase II and III clinical programs, and collaborated on vaccine and therapeutics programs for Lassa, Ebola, and SARS-CoV-2. At Focus Diagnostics, he managed the development and validation of immune response assays for over 70 vaccine and therapeutic clinical trials, facilitating the release of numerous new vaccines. Dr. Gottlieb's PhD (polyomavirus) and post-doc (hantavirus) were in virology, focusing on virus biology in host species. His extensive experience and leadership in R&D, from early-stage research to clinical trials and regulatory affairs, are now dedicated to advancing gene therapy programs at Elpida Therapeutics and treating as many children as possible.